First reported 16 Oct 2013•Latest report 4 Nov 2025
Definition
What this concern includes
Includes failures of product packaging, labels or enclosed product information to provide sufficiently visible, prominent, complete and intelligible warnings about serious hazards associated with using or misusing the product, including inhalation, poisoning, fire, choking and comparable risks.
Not included
Excludes road, premises, workplace and public-location warning signs where the warning is not part of product packaging or product information.
Excludes generic product defects or unsafe product design where the warning or labelling control is not itself deficient.
Excludes dosage, instructions or general consumer information unless the reported deficiency concerns communicating a serious product-safety hazard through packaging or accompanying product information.
Excludes warnings for a named clinical, transport or operational safety system where that system supplies the more specific supported parent boundary.
Reports
20
Distinct published reports
Individual concerns
26
A report can raise multiple concerns
Date range
2013–2025
First to latest report issue date
Stated actions
48
Described in published responses
Reports over time
Reports over time
Reports about this concern issued each year.
* 2026 is projected from reports observed to 7 Sep 2026.
Most frequent recipients
Most frequent recipients
Reports about this concern sent to each recipient.
Department of Health and Social Care5
Medicines and Healthcare products Regulatory Agency5
NHS England4
Food Standards Agency3
Care Quality Commission2
Proprietary Association of Great Britain2
Alliance Pharmaceuticals Limited1
Arjo UK Limited1
Bayer plc1
Bradford District Care NHS Foundation Trust1
British Aerosol Manufacturers' Association1
Churchgate Surgery1
Decathlon UK1
Department for Business, Energy & Industrial Strategy1
Department for Business, Innovation, Science and Trade1
Ministerial department9
Private limited company6
Executive non-departmental public body5
Medicines and medical devices regulator5
Company3
Food safety regulator3
NHS trust3
Health and social care service regulator2
Trade association2
Type not available2
Community interest company1
Company limited by guarantee1
Consumer protection enforcement body1
Education and care inspectorate1
Executive agency1
Concerns and responses across reports
Only concerns grouped under this recurring concern are included. Select any concern, action or position to view the source wording.
Manchester South
Concerns raised1
Inadequate visibility and wording of aerosol inhalation warnings
This report raised 4 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concerns
Each statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.4
Action
Developed and updated guidance for a prominent inhalation caution mark, including revised wording, placement and visibility specifications.
Stated by British Aerosol Manufacturers' AssociationStated completedThe respondent said that this action was complete when they made their response on 5 November 2025.
Action
Promote existing and updated caution labels and encourage aerosol marketers to adopt them across products placed on the UK market.
Stated by British Aerosol Manufacturers' AssociationStated in progressThe respondent said that this action was in progress when they made their response on 5 November 2025.
Action
Encourage aerosol manufacturers to adopt the updated inhalation-risk warning.
Stated by Department for Business, Innovation, Science and TradeStated plannedThe respondent said that this action was planned when they made their response on 5 November 2025.
Action
Monitor voluntary uptake of the updated warning and communicate expectations for industry adoption.
Stated by Department for Business, Innovation, Science and TradeStated plannedThe respondent said that this action was planned when they made their response on 5 November 2025.
Respondent positions A position is what a respondent says about the concern when they do not describe a specific action.1
Position
Improved on-pack labelling and point-of-use information are considered sufficient, making retail age restrictions on aerosol sales unnecessary.
Stated by British Aerosol Manufacturers' AssociationExisting arrangements considered sufficientThe respondent said that existing arrangements were sufficient, so no further action was needed.
Hampshire, Portsmouth and Southampton
Concerns raised1
Absence of a visible external warning label on flue-less liquified petroleum gas cabinet heaters
This report raised 2 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concerns
Each statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.1
Action
Request that the relevant British Standards Institution committee review warning placement and content requirements for portable gas appliances under foreseeable conditions of use.
Stated by Office for Product Safety and StandardsStated completedThe respondent said that this action was complete when they made their response on 30 July 2025.
Respondent positions A position is what a respondent says about the concern when they do not describe a specific action.1
Position
There is no evidence that the product’s ventilation warning failed the applicable regulatory and voluntary standard requirements at the time.
Stated by Office for Product Safety and StandardsDisputes the concernThe respondent disagreed with part of the concern or the basis for it.
Dorset
Concerns raised1
Absence of choking-risk warnings on adhesive gel product packaging and information leaflets
This report raised 3 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concerns
Each statement is shown once, even when linked to more than one concern.
Respondent positions A position is what a respondent says about the concern when they do not describe a specific action.3
Position
Raising denture adhesive packaging risks with product manufacturers is outside the respondent’s remit.
Stated by Care Quality CommissionOutside remitThe respondent said that this matter was outside its role or authority.
Position
Further action on denture adhesive packaging risks may be required by the coroner or Office for Product Safety and Standards.
Stated by Care Quality CommissionRedirects responsibilityThe respondent said that another organisation was responsible for deciding or taking action.
Position
Existing compliance, clear usage instructions and post-market surveillance are considered sufficient, so no product or packaging changes are proposed.
Stated by FixodentExisting arrangements considered sufficientThe respondent said that existing arrangements were sufficient, so no further action was needed.
Surrey
Concerns raised1
Food labelling requirements failing to require warnings about risks and side effects on packaging
This report raised 2 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concerns
Each statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.2
Action
Review product operations and labelling following the inquest.
Stated by Save On Supplements LtdStated completedThe respondent said that this action was complete when they made their response on 22 February 2024.
Action
Contact relevant local authorities to ascertain whether the product complies with food supplement requirements.
Stated by Food Standards AgencyStated plannedThe respondent said that this action was planned when they made their response on 22 February 2024.
Respondent positions A position is what a respondent says about the concern when they do not describe a specific action.4
Position
Overarching regulation of vitamin supplements is better addressed by the Food Standards Agency and Department of Health and Social Care.
Stated by Save On Supplements LtdRedirects responsibilityThe respondent said that another organisation was responsible for deciding or taking action.
Position
Existing legal compliance, guidance adherence, consumer information and product labelling are considered sufficient to support safe Vitamin D supplement use.
Stated by Save On Supplements LtdExisting arrangements considered sufficientThe respondent said that existing arrangements were sufficient, so no further action was needed.
Position
Policy advice on supplement composition and labelling in England is assigned to the Department of Health and Social Care.
Stated by Food Standards AgencyRedirects responsibilityThe respondent said that another organisation was responsible for deciding or taking action.
Position
Amending key supplement legislation is assigned to Ministers in the respective nations.
Stated by Food Standards AgencyRedirects responsibilityThe respondent said that another organisation was responsible for deciding or taking action.
Milton Keynes
Concerns raised1
Failure of high-protein supplement and drink labels to provide adequate warnings and safety information for people with urea cycle disorders
This report raised 2 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concerns
Each statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.1
Action
Share the coroner’s report with DHSC to support consideration of additional food labelling.
Stated by Food Standards AgencyStated plannedThe respondent said that this action was planned when they made their response on 6 September 2023.
Respondent positions A position is what a respondent says about the concern when they do not describe a specific action.2
Position
Responsibility for nutritional and broader health advice on additional food labelling rests with DHSC in England.
Stated by Food Standards AgencyRedirects responsibilityThe respondent said that another organisation was responsible for deciding or taking action.
Position
Responsibility for food compositional standards and labelling rests with DEFRA in England.
Stated by Food Standards AgencyRedirects responsibilityThe respondent said that another organisation was responsible for deciding or taking action.
Surrey
Concerns raised1
Failure to provide sufficiently prominent warnings about full-face mask risks to affected users
This report raised 3 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concerns
Each statement is shown once, even when linked to more than one concern.
Respondent positions A position is what a respondent says about the concern when they do not describe a specific action.2
Position
Product safety falls outside the organisation’s functions and grant-funded scope, so it cannot act on the reported issues.
Stated by National Trading StandardsOutside remitThe respondent said that this matter was outside its role or authority.
Position
The Office for Product Safety and Standards holds responsibility for product recalls and consumer product safety matters.
Stated by National Trading StandardsRedirects responsibilityThe respondent said that another organisation was responsible for deciding or taking action.
Northamptonshire
Concerns raised1
Failure of medical product information to clearly identify PEG existence, dose and molecular weight
This report raised 3 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concerns
Each statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.6
Action
Work with UK Approved Bodies to communicate the importance of clear PEG labelling.
Stated by Medicines and Healthcare products Regulatory AgencyStated plannedThe respondent said that this action was planned when they made their response on 3 August 2021.
Action
Engage medical-device manufacturers and other stakeholders to develop clear PEG/macrogol labelling guidelines.
Stated by Medicines and Healthcare products Regulatory AgencyStated in progressThe respondent said that this action was in progress when they made their response on 3 August 2021.
Action
Review requirements for disclosing PEG molecular weight and quantity, consulting patient representatives, clinical experts and industry.
Stated by Medicines and Healthcare products Regulatory AgencyStated plannedThe respondent said that this action was planned when they made their response on 3 August 2021.
Action
Appraise UK medical-device and medicines legislation on minimum ingredient-labelling requirements.
Stated by Medicines and Healthcare products Regulatory AgencyStated in progressThe respondent said that this action was in progress when they made their response on 3 August 2021.
Action
Continue reviewing PEG exposure data, seek external expert views and use the findings to develop labelling advice for devices and medicines.
Stated by Medicines and Healthcare products Regulatory AgencyStated in progressThe respondent said that this action was in progress when they made their response on 3 August 2021.
Action
Appraise feedback from the public consultation, including feedback on proposed medical-device labelling requirements.
Stated by Medicines and Healthcare products Regulatory AgencyStated plannedThe respondent said that this action was planned when they made their response on 3 August 2021.
Birmingham and Solihull
Concerns raised1
Lack of warnings on dashboard trays against fitting them in moving vehicles
This report raised 1 other concern. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concerns
Each statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.2
Action
Highlight the report’s safety concerns at the Heavy Vehicle Industry Forum and ask attendees to pass the information to their members.
Stated by Driver and Vehicle Standards AgencyStated plannedThe respondent said that this action was planned when they made their response on 29 December 2019.
Action
Update commercial-vehicle safety guidance to warn drivers against placing objects in lorries that restrict their view.
Stated by Driver and Vehicle Standards AgencyStated plannedThe respondent said that this action was planned when they made their response on 29 December 2019.
Respondent positions A position is what a respondent says about the concern when they do not describe a specific action.2
Position
The Department lacks authority to require warning messages on aftermarket dashboard trays about visibility risks during driving.
Stated by Department for TransportOutside remitThe respondent said that this matter was outside its role or authority.
Position
The respondent lacks authority to require warning messages on aftermarket dashboard trays.
Stated by Driver and Vehicle Standards AgencyOutside remitThe respondent said that this matter was outside its role or authority.
Manchester South
Concerns raised2
Misleading warning leaflet imagery about leaving babies unattended on multi-purpose nursing pillows
Failure to keep safety warnings attached to multi-purpose nursing pillows through resale or recycling
This report raised 2 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concerns
Each statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.1
Action
Refer concerns about the nursing pillow to the Office for Product Safety and Standards’ Product Safety Enforcement Team.
Stated by Department for Business, Energy & Industrial StrategyStated completedThe respondent said that this action was complete when they made their response on 10 May 2019.
West Yorkshire (Western)
Concerns raised1
Failure to display fire-risk warnings on all product packaging
This report raised 5 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concerns
Each statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.11
Action
Issue safety reminders and warnings to healthcare professionals about fire risks from paraffin-based emollients.
Stated by Medicines and Healthcare products Regulatory AgencyStated completedThe respondent said that this action was complete when they made their response on 30 October 2018.
Action
Write to manufacturers to include emollient fire risks in product risk analyses and provide packaging or instructions-for-use warnings.
Stated by Medicines and Healthcare products Regulatory AgencyStated completedThe respondent said that this action was complete when they made their response on 30 October 2018.
Action
Complete a Hydromol product-labelling review to improve warning prominence, clarity, content and consistency across paraffin concentrations.
Stated by Alliance Pharmaceuticals LimitedStated completedThe respondent said that this action was complete when they made their response on 30 October 2018.
Action
Add a fire-risk warning to Hydromol product labelling, explaining ignition risks involving contaminated dressings, clothing and bedding.
Stated by Alliance Pharmaceuticals LimitedStated completedThe respondent said that this action was complete when they made their response on 30 October 2018.
Stated by Alliance Pharmaceuticals LimitedStated plannedThe respondent said that this action was planned when they made their response on 30 October 2018.
Action
Undertake a cross-functional expert assessment of Hydromol labelling using information from the incident to identify further improvement opportunities.
Stated by Alliance Pharmaceuticals LimitedStated plannedThe respondent said that this action was planned when they made their response on 30 October 2018.
Action
Review proposed Hydromol labelling changes with user groups to confirm that the intended safety message is understandable.
Stated by Alliance Pharmaceuticals LimitedStated plannedThe respondent said that this action was planned when they made their response on 30 October 2018.
Action
Engage West Yorkshire Fire Service to ensure Hydromol labelling clearly explains the mechanisms of fire risk.
Stated by Alliance Pharmaceuticals LimitedStated in progressThe respondent said that this action was in progress when they made their response on 30 October 2018.
Action
Work with the MHRA and PAGB to develop a consolidated fire-risk warning for all relevant product packaging across the industry.
Stated by Alliance Pharmaceuticals LimitedStated in progressThe respondent said that this action was in progress when they made their response on 30 October 2018.
Action
Reclassify Diprobase Cream as a Class 1 medical device and complete the associated conformity assessment.
Stated by Bayer plcStated in progressThe respondent said that this action was in progress when they made their response on 30 October 2018.
Action
Launch Diprobase Cream with a fire-source warning on external packaging and in the patient information leaflet.
Stated by Bayer plcStated plannedThe respondent said that this action was planned when they made their response on 30 October 2018.
Respondent positions A position is what a respondent says about the concern when they do not describe a specific action.1
Position
Changes to medicinal-product labelling require MHRA approval, which will not be granted until its labelling review is complete.
Stated by Bayer plcUnable to actThe respondent said that a constraint prevented them from taking the relevant action.
Pin
Get email alerts
Request correction
Includes failures of product packaging, labels or enclosed product information to provide sufficiently visible, prominent, complete and intelligible warnings about serious hazards associated with using or misusing the product, including inhalation, poisoning, fire, choking and comparable risks.
